Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2015-12-15
|
BI 836858 in combination with decitabine |
acute myeloid leukemia (AML) |
2 |
Boehringer Ingelheim (Germany) |
Cancer - Oncology |
2015-12-14
|
IMO-2125 in combination with ipilimumab |
patients with previously treated metastatic melanoma |
1-2 |
Idera Pharmaceuticals (USA - CA) |
Cancer - Oncology |
2015-12-14
|
PINTA 745 |
protein energy wasting in patients with end stage renal disease |
1-2 |
Atara Biotherapeutics (USA - CA) |
Kidney diseases - Renal diseases |
2015-12-14
|
SGX301 (synthetic hypericin) |
cutaneous T-cell lymphoma |
3 |
Soligenix (USA - NJ) |
Cancer - Oncology |
2015-12-13
|
SGN-LIV1A |
LIV-1-expressing metastatic breast cancer |
1 |
Seattle Genetics (USA - WA) |
Cancer - Oncology |
2015-12-11
|
BioChaperone Lispro® U200 |
diabetes |
1b |
Adocia (France) Eli Lilly (USA - IN) |
Metabolic diseases |
2015-12-11
|
human pegivirus 2 (HPgV-2) |
hepatitis C |
|
Abbott (USA - IL) University of California San Francisco (UCSF) (USA - CA) |
Infectious diseases |
2015-12-11
|
predictive biomarker signature for vantictumab (anti-Fzd7, OMP-18R5) |
breast cancer |
|
OncoMed Pharmaceuticals (USA - CA) |
Cancer - Oncology |
2015-12-10
|
CER-001 |
familial primary hypoalphalipoproteinemia (FPHA) |
3 |
Cerenis Therapeutics (France) |
Cardiovascular diseases - Metabolic diseases - Genetic diseases - Rare diseases |
2015-12-10
|
Zalmoxis® - investigational cell therapy product TK |
high risk leukemia |
1-2 |
MolMed (Italy) |
Cancer - Oncology |
2015-12-10
|
TW001 - edaravone |
amyotrophic lateral sclerosis |
|
Treeway (The Netherlands) |
Neurodegenerative diseases - Rare diseases |
2015-12-10
|
JNJ-64041757/ADU-214 |
non small cell lung cancer |
1 |
Janssen Research & Development, a J&J company (USA - NJ) |
|
2015-12-09
|
daratumumab |
diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL) |
2 |
Janssen Research & Development, a J&J company (USA - NJ) |
Cancer - Oncology |
2015-12-09
|
ADX88178 |
|
preclinical |
Addex Therapeutics (Switzerland) |
Neurodegenerative diseases - CNS diseases |
2015-12-09
|
avelumab (MSB0010718C) |
unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro esophageal Junction |
3 |
Pfizer (USA - NY) Merck KGaA (Germany) |
Cancer - Oncology |
2015-12-09
|
avelumab (MSB0010718C) |
unresectable, recurrent or metastatic adenocarcinoma of the stomach, or of the gastro esophageal junction |
3 |
Pfizer (USA - NY) Merck KGaA (Germany) |
Cancer - Oncology |
2015-12-08
|
Alprolix® (eftrenonacog alfa - long-lasting recombinant Factor IX Fc fusion protein (rFIXFc) - BIIB 029 |
hemophilia B |
|
Biogen (USA - MA) Swedish Orphan Biovitrum SOBI (Sweden) |
Rare diseases - Genetic diseases - Hematological diseases |
2015-12-08
|
varlilumab and Tecentriq® (atezolizumab) (MPDL3280A) |
unresectable stage III or IV renal cell carcinoma (RCC)unresectable stage III or IV melanoma, triple negative breast cancer, bladder cancer, head and neck cancer or non-small cell lung cancer (NSCLC) |
1- 2 |
Celldex Therapeutics (USA - NJ) |
Cancer - Oncology |
2015-12-08
|
nintedanib |
systemic sclerosis |
3 |
Boehringer Ingelheim (Germany) |
Autoimmune diseases - Rare diseases |
2015-12-08
|
eltoprazine |
elderly patients with Alzheimer's dementia who are aggressive |
2 |
Amarantus BioScience (USA – CA) |
Neurodegenerative diseases |